The precautions for use of Optist ophthalmic solution (Lantanoprost) have been changed in accordance with the approval change order as a result of the re-examination by the Food and Drug Administration (Drug Management Team-No. 20951, effective date 2006. 11. 02).


For further details, please refer to the ‘Product Introduction’ section and attached documents.